ĐẠI HỌC QUỐC GIA HÀ NỘI TRƯỜNG ĐẠI HỌC KHOA HỌC TỰ NHIÊN TRẦN THỊ YẾN NGHIÊN CỨU QUI TRÌNH TỔNG HỢP LIÊN TỤC VÀ TINH CHẾ CELECOXIB LUẬN VĂN THẠC SĨ KHOA HỌC ĐẠI HỌC QUỐC GIA HÀ NỘI TRƯỜNG ĐẠI HỌC KHOA HỌC TỰ NHIÊN TRẦN THỊ YẾN NGHIÊN CỨU QUI TRÌNH TỔNG HỢP LIÊN TỤC VÀ TINH CHẾ CELECOXIB Chuyên nghành: Hóa hữu Mã số: 60440114 LUẬN VĂN THẠC SĨ KHOA HỌC Người hướng dẫn khoa học: TS Ngô Quốc Anh Hà Nội - 2016 TÀI LIỆU THAM KHẢO A Tiếng Việt Đào Văn Phan (2007), Dược lý học, tập 1, Nhà xuất Giáo dục, Hà Nội Mai Tất Tố (2007), Dược lý học, tập 2, Nhà xuất Y học, Hà Nội (2010), Vidal Việt Nam, Nhà xuất CMPMedica Asia Pte Ltd, Tp Hồ Chí Minh B Tiếng Anh Anumula, et al (2008), Process for preparation of celecoxib, US patent, US 20080234491A1 Beuck M (1999), "Nonsteroidal antiinflammatory drugs: A new generation of cyclooxygenase inhibitors", Angew Chem Int Ed., 38, pp 0631-0633 Coruzzi G., Venturi N., Spaggiari S (2007), " Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: Selective cox-2 inhibitors and beyond", Acta Biomed, 78, pp 96-110 Davies N M., et al (2000), "Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor", Clin Pharmacokinet, 38(3), pp 225-242 Farooq M., et al (2008), " Cardiovascular risks of cox inhibition: Current perspectives", A.S.Expert Opin Pharmacother, 9, pp 1311-1319 Ferro, et al (2004), Polymorphic crystalline forms of celecoxib, United States Patent, US 20040087640A1(5/2004) 10 Frampton J E., Keating G M (2007), "Celecoxib: A review of its use in the management of arthritis and acute pain", Drugs, 67(16), pp 2433-2472 11 Furniss B S., et al (1989), "Vogel's textbook of practical organic chemistry", Longman Scientific & technical, 5th edition, pp 959 12 Gandey A (2011), "All nonsteroidal anti-inflammatory drugs have cardiovascular ricks", BMJ 13 Harris R E., et al (2000), "Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase inhibitor", Cancer Res, 60(8), pp 2101-2103 14 Jeffery S C (2000), "Inhibitors of cyclooxygenase-2", Exp Opin Ther Patents, 10(7), pp 1011-1020 15 Jones R., et al ( 2008), "Gastrointestinal and cardiovascular risks of nonsteroidal antiinflammatory drugs", Am J Med., 121, pp 464-474 16 Kalgutkar A S , Lawrence J M (1998), "Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents", Current Opinion in Chemical Biology, 2, pp 482-490 17 Letendre, et al (2007), "Synthesis of diaryl pyrazoles", US patent, US 20070004924A1(1/2007) 18 Li J J , et al (2004), "Anti-inflammatory cyclooxygenase-2 selective inhibitors: Celecoxib (celebrex) and rofecoxib (vioxx)", Contemporary Drug Synthesis, pp 11-19 19 Loewen P S (2002), "Review of the selective cox-2 inhibitors celecoxib and rofecoxib: Focus on clinical aspects", CJEM, 4(4), pp 268-275 20 Lynette M O (2006), "Synthesis of celecoxib via 1,3-dipolar cycloaddition", ScienceDirect, 47(45), pp 7943-7946 21 Masferrer J L., et al (2000), "Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors", Cancer Res, 60(5), pp 1306-1311 22 Micheal B S , Jerry March (2001), "March's advanced organic chemistry: Reactions, mechanisms and structure", Wiley - Interscience, 5th edition, pp 1556 23 Moore R A., et al (2005), "Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systematic review and meta-analysis of information from company clinical trial reports", Arthritis Res Ther, 7(3), pp R644-665 24 O'Shea, et al (2001), Synthesis of 4-[(5-substituted phenyl)-3-substituted-lhpyrazol-l-yljbenzenesulfonamide, United States Patent, S006232472B1 (5/2001) 25 Penning T D., et al (1997), "Synthesis and biological evaluation of the 1,5diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4methylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]benze nesulfonamide (sc58635, celecoxib)", J Med Chem, 40(9), pp 1347-1365 26 Reddy B S., et al (2000), "Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis", Cancer Res, 60(2), pp 293-297 27 Reddy M., et al (2003), Process for the preparation of 1,5-diarylpyraroles, World Intellectual Property Organization, WO 03/024400 A2.(3/2003) 28 Sanghi S., et al (2006), "Cyclooxygenase-2 inhibitors: A painful lesson", Cardiovasc Hematol Disord Drug Targets, 6(2), pp 85-100 29 Silverstein F E., et al (2000), "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The class study: A randomized controlled trial Celecoxib long-term arthritis safety study", JAMA, 284(10), pp 1247-1255 30 Simon L S., et al (1999), "Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial", JAMA, 282(20), pp 1921-1928 31 Talley J J., et al (2003), Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation, US patent, 6,586,603,B1(6/2003) 32 Vane J ( 1994), "Towards a better aspirin ", Nature, 367, pp 215-216 33 Zhuang, et al (2004), Stable amorphous celecoxib composite and process therefor, Patent Application Publication, US 20040030151A1(2/2004) 34 Zhi B., Estates H.; Newaz M., PalatineIll.( 1999), U.S Pat Nos 5,910,597